China SXT Pharmaceuticals, Inc. (SXTC) Balance Sheet
SXTC balance sheet, FY2026
March 31, 2026 · U.S. dollars$34.8M assets = $5.0M liabilities + $29.7M equity
Both columns are drawn to the same scale: what SXTC owns equals what it owes plus shareholders’ equity. Hover a block for its value.
SXTC financial health
Descriptive bands, not a rating. Fiscal FY2026.
SXTC balance sheet trends, FY2017–FY2026
| Metric | Trend | Then | Latest | Change |
|---|---|---|---|---|
| Total assets | $5.4MFY2017 | $34.8MFY2026 | +22.9%/yr | |
| Total liabilities | $3.6MFY2017 | $5.0MFY2026 | +3.9%/yr | |
| Shareholders’ equity | $1.9MFY2017 | $29.7MFY2026 | +36.1%/yr | |
| Cash & short-term investments | $65,570FY2017 | $28.2MFY2026 | +96.1%/yr | |
| Total debt | $302,168FY2017 | $1.1MFY2026 | +15.7%/yr | |
| Net cash (debt) | −$236,598FY2017 | $27.1MFY2026 | +$27.3M | |
| Working capital | $1.3MFY2017 | $30.2MFY2026 | +$28.8M | |
| Current ratio | 1.37FY2017 | 7.93FY2026 | +6.56 | |
| Debt / equity | 0.16FY2017 | 0.04FY2026 | −0.13 |
Change is the average annual growth (CAGR) or the difference between the first and latest year.
SXTC assets
SXTC liabilities and equity
SXTC debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease obligations.
SXTC balance sheet
| FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||
| Cash & short-term investments | $28.2M | $18.1M | $12.1M | $17.4M | $15.5M | $13.3M | $7.3M | $9.1M | $560,252 | $65,570 |
| Cash & equivalents | $28.2M | $18.1M | $12.1M | $17.4M | $15.5M | $13.3M | $7.3M | $9.1M | $560,252 | $65,570 |
| Short-term investments | — | $137,804 | — | — | — | — | — | — | $98,000 | — |
| Receivables | $3.2M | $1.9M | $1.3M | $1.3M | $3.4M | $7.8M | $10.6M | $4.9M | $3.9M | $3.2M |
| Inventory | $3.0M | $828,053 | $809,757 | $531,254 | $1.1M | $859,696 | $892,767 | $1.0M | $1.3M | $1.0M |
| Other current assets | $144,970 | $469,267 | $6,842 | $276,946 | $2.5M | $1.3M | $809,099 | $516,890 | $361,931 | $615,148 |
| Total current assets | $34.5M | $21.3M | $14.2M | $19.5M | $22.5M | $23.2M | $19.6M | $15.6M | $6.1M | $4.9M |
| Property, plant & equipment (net) | $238,524 | $355,209 | $564,693 | $1.3M | $1.6M | $1.8M | $1.9M | $1.8M | $1.5M | $485,294 |
| Goodwill & intangible assets | $6,328 | $11,808 | $19,101 | $27,868 | $38,762 | $45,800 | $50,052 | $61,096 | $60,673 | $41,004 |
| Long-term investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other non-current assets | $0 | $0 | $8.3M | $8.7M | $9.5M | $9.5M | $112,839 | $13,504 | $6,174 | $0 |
| Total assets | $34.8M | $21.7M | $23.1M | $29.6M | $33.5M | $34.5M | $21.7M | $17.5M | $7.7M | $5.4M |
| Liabilities | ||||||||||
| Accounts payable | $497,648 | $1.2M | $1.3M | $1.4M | $1.5M | $1.5M | $1.9M | $1.7M | $2.4M | $1.3M |
| Short-term debt | $423,154 | $772,194 | $2.4M | $3.4M | $10.7M | $37,122 | $6.7M | $2.7M | $385,121 | $302,168 |
| Deferred revenue | $104,423 | $58,627 | $187,665 | $165,534 | $77,366 | $257,449 | $298,042 | $57,553 | $292,947 | $585,969 |
| Total current liabilities | $4.3M | $6.0M | $8.9M | $14.5M | $17.1M | $18.6M | $12.3M | $6.3M | $4.4M | $3.6M |
| Long-term debt | $644,390 | $96,264 | $117,129 | $117,862 | $0 | $6,292 | $36,511 | $0 | $0 | $0 |
| Lease obligations | $121,421 | $176,648 | $235,848 | $306,050 | $0 | — | — | — | — | — |
| Other long-term liabilities | $53,442 | $115,419 | $177,538 | $247,961 | $1 | $0 | $0 | $41,706 | $0 | $0 |
| Total liabilities | $5.0M | $6.2M | $9.2M | $14.9M | $17.1M | $18.6M | $12.3M | $6.4M | $4.4M | $3.6M |
| Shareholders' equity | ||||||||||
| Common stock & paid-in capital | $64.1M | $44.5M | $4.4M | $913,785 | $162,468 | $62,057 | $34,667 | $22,706 | $20,000 | $20,000 |
| Retained earnings (deficit) | −$34.2M | −$28.0M | −$24.7M | −$21.6M | −$15.7M | −$10.0M | −$7.2M | $3.1M | $1.5M | $357,064 |
| Accumulated other comprehensive income | −$197,878 | −$1.1M | −$1.0M | −$197,571 | $956,142 | $527,786 | −$590,660 | $50,395 | $257,373 | $11,825 |
| Total shareholders' equity | $29.7M | $15.4M | $13.9M | $14.7M | $16.4M | $16.0M | $9.4M | $11.1M | $3.3M | $1.9M |
| Key figures | ||||||||||
| Total debt | $1.1M | $983,877 | $2.6M | $3.8M | $10.7M | $43,414 | $6.7M | $2.8M | $385,121 | $302,168 |
| Net cash (debt) | $27.1M | $17.1M | $9.4M | $13.6M | $4.8M | $13.3M | $563,156 | $6.3M | $175,131 | −$236,598 |
| Working capital | $30.2M | $15.3M | $5.3M | $5.0M | $5.3M | $4.7M | $7.4M | $9.3M | $1.7M | $1.3M |
| Tangible book value | $29.7M | $15.4M | $13.9M | $14.7M | $16.4M | $15.9M | $9.4M | $11.0M | $3.2M | $1.8M |
| Current ratio | 7.93 | 3.54 | 1.60 | 1.35 | 1.31 | 1.25 | 1.60 | 2.47 | 1.40 | 1.37 |
| Quick ratio | 7.22 | 3.33 | 1.51 | 1.29 | 1.10 | 1.14 | 1.46 | 2.22 | 1.02 | 0.91 |
| Debt / equity | 0.04 | 0.06 | 0.19 | 0.26 | 0.65 | 0.00 | 0.72 | 0.25 | 0.12 | 0.16 |
| Equity / assets | 85.5% | 71.3% | 60.2% | 49.7% | 49.0% | 46.2% | 43.3% | 63.6% | 42.9% | 34.1% |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||||
| Cash & short-term investments | $28.2M | $28.2M | $28.3M | $21.2M | $21.3M | $18.1M | $18.2M | — | $18.5M | $12.1M | $12.1M | $11.5M |
| Cash & equivalents | $28.2M | $28.2M | $28.2M | $21.2M | $21.2M | $18.1M | $18.1M | — | $18.5M | $12.1M | $12.1M | $11.5M |
| Short-term investments | — | — | $144,970 | — | $140,469 | — | $137,804 | — | — | — | — | — |
| Receivables | $3.2M | $931,567 | $931,567 | $2.9M | $1.3M | $1.3M | $1.3M | $0 | $1.7M | $1.3M | $1.3M | $1.3M |
| Inventory | $3.0M | $777,059 | $3.0M | $751,346 | $1.8M | $828,053 | $1.1M | $0 | $1.6M | $794,855 | $809,757 | $581,317 |
| Other current assets | $144,970 | $4.6M | $2.3M | $1.3M | $1.6M | $1.1M | $629,230 | $21.0M | $223,007 | $53,378 | $38,476 | $137,978 |
| Total current assets | $34.5M | $34.5M | $34.5M | $26.0M | $26.0M | $21.3M | $21.3M | $21.0M | $22.0M | $14.2M | $14.2M | $13.5M |
| Property, plant & equipment (net) | $238,524 | $238,524 | $238,524 | $302,357 | $302,357 | $355,209 | $355,209 | $0 | $443,210 | $564,693 | $564,693 | $1.1M |
| Goodwill & intangible assets | $6,328 | $6,328 | $6,328 | $8,532 | $8,532 | $11,808 | $11,808 | $0 | $15,897 | $19,101 | $19,101 | $22,514 |
| Long-term investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other non-current assets | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $9.0M | $8.5M | $8.3M | $8.3M | $0 |
| Total assets | $34.8M | $34.8M | $34.8M | $26.4M | $26.4M | $21.7M | $21.7M | $30.0M | $31.0M | $23.1M | $23.1M | $14.6M |
| Liabilities | ||||||||||||
| Accounts payable | $497,648 | $497,648 | $497,648 | $530,662 | $530,662 | $1.2M | $1.2M | — | $1.7M | $1.3M | $1.3M | $1.3M |
| Short-term debt | $423,154 | — | $423,154 | $1.0M | $1.0M | — | $772,194 | — | $9.6M | — | $3.4M | $3.2M |
| Deferred revenue | $104,423 | — | — | $65,057 | $58,627 | — | — | — | $187,665 | — | $1.6M | $190,193 |
| Total current liabilities | $4.3M | $4.3M | $4.3M | $6.0M | $6.0M | $6.0M | $6.0M | — | $15.7M | $8.9M | $8.9M | $9.2M |
| Long-term debt | $0 | $644,390 | $0 | $73,102 | $0 | $96,264 | $0 | $0 | $0 | $117,129 | $0 | $106,575 |
| Lease obligations | — | $121,421 | — | $149,279 | — | $176,648 | — | — | — | $235,848 | — | $261,108 |
| Other long-term liabilities | $697,832 | $53,442 | $697,832 | $85,160 | $158,262 | $115,419 | $211,683 | — | $298,011 | $177,538 | $294,667 | $204,937 |
| Total liabilities | $5.0M | $5.0M | $5.0M | $6.1M | $6.1M | $6.2M | $6.2M | $19.8M | $16.0M | $9.2M | $9.2M | $9.5M |
| Shareholders' equity | ||||||||||||
| Common stock & paid-in capital | $64.1M | — | $64.1M | $55.4M | $55.4M | — | $44.5M | — | $7.7M | — | $4.4M | $1.5M |
| Retained earnings (deficit) | −$34.2M | −$34.2M | −$34.2M | −$34.4M | −$34.4M | −$28.0M | −$28.0M | — | −$25.5M | −$24.7M | −$24.7M | −$31.3M |
| Accumulated other comprehensive income | −$197,878 | — | −$197,878 | −$766,991 | −$766,990 | — | −$1.1M | — | −$568,852 | — | −$1.0M | −$1.0M |
| Total shareholders' equity | $29.7M | $29.7M | $29.7M | $20.2M | $20.2M | $15.4M | $15.4M | $10.2M | $15.0M | $13.9M | $13.9M | $5.1M |
| Key figures | ||||||||||||
| Total debt | $1.1M | $644,390 | $1.1M | $1.2M | $1.2M | $96,264 | $983,877 | — | $9.9M | $117,129 | $3.7M | $3.5M |
| Net cash (debt) | $27.1M | $27.5M | $27.2M | $20.0M | $20.1M | $18.0M | $17.3M | — | $8.6M | $12.0M | $8.4M | $7.9M |
| Working capital | $30.2M | $30.2M | $30.2M | $20.1M | $20.1M | $15.3M | $15.3M | — | $6.3M | $5.3M | $5.3M | $4.3M |
| Tangible book value | $29.7M | $29.7M | $29.7M | $20.2M | $20.2M | $15.4M | $15.4M | $10.2M | $15.0M | $13.9M | $13.9M | $5.1M |
| Book value per share | — | — | — | — | $8.28 | — | $6.32 | — | — | — | — | — |
| Shares outstanding | — | — | — | — | 2.4M | — | 2.4M | — | — | — | — | — |
| Current ratio | 7.93 | 7.93 | 7.93 | 4.37 | 4.37 | 3.54 | 3.54 | — | 1.40 | 1.60 | 1.60 | 1.47 |
| Quick ratio | 7.22 | 6.69 | 6.73 | 4.03 | 3.80 | 3.23 | 3.25 | — | 1.29 | 1.50 | 1.50 | 1.39 |
| Debt / equity | 0.04 | 0.02 | 0.04 | 0.06 | 0.06 | 0.01 | 0.06 | — | 0.66 | 0.01 | 0.27 | 0.69 |
| Equity / assets | 85.5% | 85.5% | 85.5% | 76.8% | 76.8% | 71.3% | 71.3% | 34.0% | 48.5% | 60.2% | 60.2% | 34.8% |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported (latest annual report filed July 1, 2026); data from EODHD.
SXTC financial position
At the end of fiscal 2026 (March 31, 2026), China SXT Pharmaceuticals had total assets of $34.8 million (up 60.4% from a year earlier), total liabilities of $5.0 million and shareholders' equity of $29.7 million. It held $28.2 million in cash and short-term investments against $1.1 million of debt, a net cash position of $27.1 million. Its current ratio was 7.93. In the latest quarter (ended June 30, 2026) total assets were $34.8 million and equity $29.7 million.
Related: SXTC income statement, SXTC cash flow statement, SXTC key metrics. See the SXTC stock overview for the latest quote and news.
SXTC balance sheet FAQ
What are China SXT Pharmaceuticals's total assets?
China SXT Pharmaceuticals reported total assets of $34.8 million at the end of fiscal 2026 (March 31, 2026), compared with $21.7 million a year earlier.
How much debt does China SXT Pharmaceuticals have?
China SXT Pharmaceuticals had $1.1 million of total debt at the end of fiscal 2026, including short-term borrowings and lease obligations. Its debt-to-equity ratio was 0.04.
How much cash does China SXT Pharmaceuticals have?
China SXT Pharmaceuticals held $28.2 million in cash and short-term investments at the end of fiscal 2026; with $1.1 million of debt that is net cash of $27.1 million.
What is China SXT Pharmaceuticals's book value?
China SXT Pharmaceuticals's shareholders' equity (book value) was $29.7 million at the end of fiscal 2026.
What is China SXT Pharmaceuticals's current ratio?
China SXT Pharmaceuticals had current assets of $34.5 million and current liabilities of $4.3 million, a current ratio of 7.93 (it can cover its short-term obligations).
How much goodwill does China SXT Pharmaceuticals have?
China SXT Pharmaceuticals carried $0.0 million of goodwill and intangible assets, 0.0% of total assets, at the end of fiscal 2026.